Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 9 August 2022, 17:09 HKT/SGT
Share:
    

Source: Eisai
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care

TOKYO, Aug 9, 2022 - (JCN Newswire) - Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan's aging society.

New insurance products and services will be developed by mutually leveraging Eisai's wealth of experience and network in drug discovery and disease awareness activities in the field of dementia, which it has built up over many years, and LIFENET's know-how and technologies cultivated in insurance products and related services. Furthermore, Eisai and LIFENET will promote the creation of healthcare solutions utilizing various data and customer touchpoint owned by both companies, and expand the ecosystem that contributes to solving social issues.
Under the terms of the agreement, Eisai will obtain LIFENET common stock worth 300 million yen through market transaction.

Under the medium-term business plan "EWAY Future & Beyond", which began in April 2021, Eisai is expanding its main role in healthcare, that is, we should contribute not only to people in the medical domain but also to people in the daily living domain. Eisai aim's to evolve into a company that empowers them "to realize their fullest life" by creating solutions based on science and data in the fields with high unmet medical needs where Eisai has the greatest strength, through an ecosystem developed in collaboration with other industries. This alliance will accelerate the building of a dementia ecosystem that contributes through prevention, treatment, and aftercare in a comprehensive manner.

LIFENET has worked with other industry partners to provide products and services that meet the needs of the times. Through this alliance, as stated in LIFENET Manifesto, LIFENET will continue providing health and wellness tips beyond the framework of life insurance to create value in our policyholders' lives, while creating a precedent for future generations as to what life insurance is (and should be) all about.

Eisai and LIFENET will contribute to solving social issues through the creation of an ecosystem while pursuing the possibility of collaborations with other companies and organizations that support the objectives of the two companies' activities.

For more information, visit www.eisai.com/news/2022/pdf/enews202261pdf.pdf.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: